niacin has been researched along with Non-alcoholic Fatty Liver Disease in 9 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "NAFLD was defined using the United States fatty liver index (US-FLI)." | 5.91 | Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018. ( Hu, Y; Pan, J; Pang, N; Yang, L, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease." | 5.42 | Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015) |
| "Niacin treatment to rats with preexisting hepatic steatosis induced by the HF diet significantly regressed steatosis." | 5.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
| "NAFLD was defined using the United States fatty liver index (US-FLI)." | 1.91 | Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018. ( Hu, Y; Pan, J; Pang, N; Yang, L, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world." | 1.56 | Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. ( Cao, Z; Lai, X; Shi, Y; Ye, L; Zhou, N, 2020) |
| "Niacin treatment was started from week 5 until the end of the study." | 1.56 | Niacin increases diet-induced hepatic steatosis in B6129 mice. ( Fang, H; Graff, EC; Judd, RL; Li, Z; McCafferty, KJ, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in industrialized countries, yet its pathophysiology is incompletely understood." | 1.42 | Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. ( Becker, T; Beldi, G; Brosch, M; Brückner, S; Erhart, W; Fahrner, R; Gruodyte, A; Hampe, J; Hinrichsen, H; Itzel, T; Landrock, A; Patsenker, E; Richter, K; Röcken, C; Schafmayer, C; Schreiber, S; Sipos, B; Stickel, F; Teufel, A; Vollnberg, B; von Schönfels, W, 2015) |
| "Non-Alcoholic Fatty Liver Disease (NAFLD) is a common liver disorder, characterized by an excessive lipids deposition within the hepatic tissue." | 1.42 | Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice. ( Baranska, M; Chlopicki, S; Kochan, K; Kostogrys, R; Krafft, C; Maslak, E, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease." | 1.42 | Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015) |
| "Niacin treatment to rats with preexisting hepatic steatosis induced by the HF diet significantly regressed steatosis." | 1.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Cardoso-Lezama, I | 1 |
| Fuentes-Figueroa, MÁ | 1 |
| Ramos-Tovar, E | 1 |
| Márquez-Quiroga, LV | 1 |
| Ortiz-Fernández, A | 1 |
| Vargas-Pozada, EE | 1 |
| Arellanes-Robledo, J | 1 |
| Tsutsumi, V | 1 |
| Muriel, P | 1 |
| Pan, J | 1 |
| Hu, Y | 1 |
| Pang, N | 1 |
| Yang, L | 1 |
| Ye, L | 1 |
| Cao, Z | 1 |
| Lai, X | 1 |
| Shi, Y | 1 |
| Zhou, N | 1 |
| Fang, H | 1 |
| Li, Z | 1 |
| Graff, EC | 1 |
| McCafferty, KJ | 1 |
| Judd, RL | 1 |
| Ganji, SH | 2 |
| Kukes, GD | 1 |
| Lambrecht, N | 1 |
| Kashyap, ML | 2 |
| Kamanna, VS | 2 |
| van den Hoek, AM | 1 |
| van der Hoorn, JW | 1 |
| Maas, AC | 1 |
| van den Hoogen, RM | 1 |
| van Nieuwkoop, A | 1 |
| Droog, S | 1 |
| Offerman, EH | 1 |
| Pieterman, EJ | 1 |
| Havekes, LM | 1 |
| Princen, HM | 1 |
| von Schönfels, W | 1 |
| Patsenker, E | 1 |
| Fahrner, R | 1 |
| Itzel, T | 1 |
| Hinrichsen, H | 1 |
| Brosch, M | 1 |
| Erhart, W | 1 |
| Gruodyte, A | 1 |
| Vollnberg, B | 1 |
| Richter, K | 1 |
| Landrock, A | 1 |
| Schreiber, S | 1 |
| Brückner, S | 1 |
| Beldi, G | 1 |
| Sipos, B | 1 |
| Becker, T | 1 |
| Röcken, C | 1 |
| Teufel, A | 1 |
| Stickel, F | 1 |
| Schafmayer, C | 1 |
| Hampe, J | 1 |
| Kochan, K | 1 |
| Maslak, E | 1 |
| Krafft, C | 1 |
| Kostogrys, R | 1 |
| Chlopicki, S | 1 |
| Baranska, M | 1 |
9 other studies available for niacin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway.
Topics: Animals; Humans; Inflammasomes; Mice; Mice, Inbred C57BL; Niacin; NLR Family, Pyrin Domain-Containin | 2023 |
Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018.
Topics: Diet; Humans; Niacin; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Nutritional Status; Unit | 2023 |
Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Gene Knockdown Techniques; Hep G2 Cells; Humans; Lipogene | 2020 |
Niacin increases diet-induced hepatic steatosis in B6129 mice.
Topics: Animals; Diet, High-Fat; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipoproteins, V | 2020 |
Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Disease Progression; Fatty | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol E | 2014 |
Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites.
Topics: Animals; Biopsy; Dietary Supplements; Gas Chromatography-Mass Spectrometry; Humans; Hydroquinones; L | 2015 |
Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice.
Topics: Animals; Apolipoproteins E; Diet, High-Fat; Dietary Carbohydrates; Dietary Proteins; Lipid Droplets; | 2015 |
Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Topics: Diacylglycerol O-Acyltransferase; Hepatocytes; Humans; Hypolipidemic Agents; Interleukin-8; Lipid Me | 2015 |